BioCryst Pharmaceuticals | BCRX - Gross Profit On Sales


BioCryst Pharmaceuticals reported $214.41M in Gross Profit on Sales for its fiscal quarter ending in June of 2026.





Gross Profit On Sales Change Date
Alnylam Pharmaceuticals USD 992.69M 167.68M Jun/2026
BioCryst Pharmaceuticals USD 214.41M 61.36M Jun/2026
Chugai Pharma JPY 237.37B 21.38B Jun/2026
Daiichi Sankyo JPY 287.15B 152.68B Mar/2026
DBV Technologies USD 2.77M 33.21M Sep/2025
Enanta Pharmaceuticals -22.29M 23.75M Dec/2024
Gilead Sciences USD 6.8B 1.29B Jun/2026
GlaxoSmithKline GBP 6.51B 757M Jun/2026
Glaxosmithkline GBP 5.75B 2.99B Mar/2026
Incyte USD 1.57B 400.89M Jun/2026
Ionis Pharmaceuticals USD 265M 22M Jun/2026
Karyopharm Therapeutics USD 33.72M 1.13M Mar/2026
Neurocrine Biosciences USD 800.7M 12.8M Mar/2026
Novavax USD 125.04M 76.09M Dec/2025
PTC Therapeutics USD 232.94M 84.56M Mar/2026
Regeneron Pharmaceuticals USD 3.71B 778.2M Jun/2026
Roche Holding CHF 22.69B 600M Jun/2026
Sarepta Therapeutics USD 251.15M 370.2M Jun/2026
Ultragenyx Pharmaceutical USD 180M 74M Jun/2026
Vertex Pharmaceuticals USD 2.84B 242.4M Jun/2026